Anthropic stopped just selling models. On June 30 it launched an internal drug discovery program aimed at “neglected diseases” — conditions where the biology is well understood but no big pharma bothers, because there’s no money in it.
What it actually is
Two things. First, real preclinical drug programs run inside Anthropic. Second, Claude Science, a research workbench wiring Claude into 60+ genomic, proteomic and chemistry databases, plus tools like PubMed and Jupyter — it can run single-cell RNA sequencing or CRISPR design on its own. The workbench is in beta for Pro, Max, Team and Enterprise users, not an open API. The logic is a loop: make drugs yourself, learn what the AI needs, sell that AI back to biopharma. Novo Nordisk and the Allen Institute are already customers.
Why it matters
Anthropic is dogfooding its own science AI on a problem the market ignores, and backing it with 50,000 research grants worth up to $30K in credits each — applications close July 15. It’s also the starting gun: Anthropic, Google and OpenAI are now fighting head-on over AI drug discovery.
You Might Also Like
- 13b Into Openai yet Microsoft Copilot Cowork Runs on Anthropic Claude
- Anthropic to Acquire Stainless for 300m Buying the Developer Pipe to Openai and Google
- Anthropic Agent sdk Metered Credits Openclaw Reinstated June 15 Splits Your Claude Subscription in two
- Anthropic Just Launched Code Review in Claude Code and 54 of prs now get Real Feedback
- Claude Replay Turns Your Anthropic Claude Code Sessions Into Shareable Video Like Replays
Top AI Product 
Leave a comment